vs

Side-by-side financial comparison of BioNexus Gene Lab Corp (BGLC) and Natera, Inc. (NTRA). Click either name above to swap in a different company.

Natera, Inc. is the larger business by last-quarter revenue ($665.5M vs $483.8K, roughly 1375.7× BioNexus Gene Lab Corp). Natera, Inc. runs the higher net margin — 7.1% vs -214.2%, a 221.3% gap on every dollar of revenue. On growth, Natera, Inc. posted the faster year-over-year revenue change (39.8% vs -80.8%). Natera, Inc. produced more free cash flow last quarter ($37.8M vs $960.1K). Over the past eight quarters, Natera, Inc.'s revenue compounded faster (34.5% CAGR vs -54.9%).

BioNexus Gene Lab Corp is a biotechnology company specializing in molecular diagnostic testing, genetic analysis, and related life science solutions. It caters to healthcare institutions, research organizations, and individual customers, with its primary operational and market focus on the Southeast Asian region.

Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendment...

BGLC vs NTRA — Head-to-Head

Bigger by revenue
NTRA
NTRA
1375.7× larger
NTRA
$665.5M
$483.8K
BGLC
Growing faster (revenue YoY)
NTRA
NTRA
+120.6% gap
NTRA
39.8%
-80.8%
BGLC
Higher net margin
NTRA
NTRA
221.3% more per $
NTRA
7.1%
-214.2%
BGLC
More free cash flow
NTRA
NTRA
$36.9M more FCF
NTRA
$37.8M
$960.1K
BGLC
Faster 2-yr revenue CAGR
NTRA
NTRA
Annualised
NTRA
34.5%
-54.9%
BGLC

Income Statement — Q4 2025 vs Q4 2025

Metric
BGLC
BGLC
NTRA
NTRA
Revenue
$483.8K
$665.5M
Net Profit
$-1.0M
$47.3M
Gross Margin
-0.8%
Operating Margin
-213.5%
-3.4%
Net Margin
-214.2%
7.1%
Revenue YoY
-80.8%
39.8%
Net Profit YoY
-197.5%
187.9%
EPS (diluted)
$0.36

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BGLC
BGLC
NTRA
NTRA
Q4 25
$483.8K
$665.5M
Q3 25
$2.5M
$592.2M
Q2 25
$2.3M
$546.6M
Q1 25
$2.1M
$501.8M
Q4 24
$2.5M
$476.1M
Q3 24
$2.6M
$439.8M
Q2 24
$2.0M
$413.4M
Q1 24
$2.4M
$367.7M
Net Profit
BGLC
BGLC
NTRA
NTRA
Q4 25
$-1.0M
$47.3M
Q3 25
$-709.0K
$-87.5M
Q2 25
$-616.2K
$-100.9M
Q1 25
$-623.3K
$-66.9M
Q4 24
$-348.3K
$-53.8M
Q3 24
$-1.3M
$-31.6M
Q2 24
$199.1K
$-37.5M
Q1 24
$-103.8K
$-67.6M
Gross Margin
BGLC
BGLC
NTRA
NTRA
Q4 25
-0.8%
Q3 25
14.8%
Q2 25
16.3%
Q1 25
16.1%
Q4 24
12.3%
Q3 24
12.4%
Q2 24
14.6%
Q1 24
15.3%
Operating Margin
BGLC
BGLC
NTRA
NTRA
Q4 25
-213.5%
-3.4%
Q3 25
-27.6%
-16.5%
Q2 25
-27.0%
-20.2%
Q1 25
-28.9%
-15.8%
Q4 24
-16.5%
-13.6%
Q3 24
-50.9%
-8.9%
Q2 24
13.1%
-10.6%
Q1 24
-3.3%
-20.2%
Net Margin
BGLC
BGLC
NTRA
NTRA
Q4 25
-214.2%
7.1%
Q3 25
-27.9%
-14.8%
Q2 25
-27.3%
-18.5%
Q1 25
-29.2%
-13.3%
Q4 24
-13.8%
-11.3%
Q3 24
-51.1%
-7.2%
Q2 24
10.1%
-9.1%
Q1 24
-4.4%
-18.4%
EPS (diluted)
BGLC
BGLC
NTRA
NTRA
Q4 25
$0.36
Q3 25
$-0.40
$-0.64
Q2 25
$-0.34
$-0.74
Q1 25
$-0.04
$-0.50
Q4 24
$0.55
$-0.41
Q3 24
$-0.75
$-0.26
Q2 24
$0.11
$-0.30
Q1 24
$-0.01
$-0.56

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BGLC
BGLC
NTRA
NTRA
Cash + ST InvestmentsLiquidity on hand
$2.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$8.6M
$1.7B
Total Assets
$9.3M
$2.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BGLC
BGLC
NTRA
NTRA
Q4 25
$2.5M
Q3 25
$1.0M
Q2 25
$16.0M
Q1 25
$17.8M
Q4 24
$2.9M
$22.7M
Q3 24
$29.5M
Q2 24
$90.3M
Q1 24
$69.1M
Stockholders' Equity
BGLC
BGLC
NTRA
NTRA
Q4 25
$8.6M
$1.7B
Q3 25
$6.8M
$1.3B
Q2 25
$7.5M
$1.2B
Q1 25
$7.8M
$1.2B
Q4 24
$8.3M
$1.2B
Q3 24
$9.4M
$878.5M
Q2 24
$9.5M
$836.5M
Q1 24
$9.3M
$794.1M
Total Assets
BGLC
BGLC
NTRA
NTRA
Q4 25
$9.3M
$2.4B
Q3 25
$7.6M
$1.8B
Q2 25
$9.4M
$1.8B
Q1 25
$9.5M
$1.7B
Q4 24
$10.4M
$1.7B
Q3 24
$11.0M
$1.6B
Q2 24
$11.1M
$1.5B
Q1 24
$11.2M
$1.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BGLC
BGLC
NTRA
NTRA
Operating Cash FlowLast quarter
$961.1K
$73.9M
Free Cash FlowOCF − Capex
$960.1K
$37.8M
FCF MarginFCF / Revenue
198.5%
5.7%
Capex IntensityCapex / Revenue
0.2%
5.4%
Cash ConversionOCF / Net Profit
1.56×
TTM Free Cash FlowTrailing 4 quarters
$-1.9M
$109.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BGLC
BGLC
NTRA
NTRA
Q4 25
$961.1K
$73.9M
Q3 25
$-1.2M
$59.4M
Q2 25
$-737.9K
$37.6M
Q1 25
$-824.1K
$44.5M
Q4 24
$219.2K
$52.9M
Q3 24
$-1.6M
$51.8M
Q2 24
$-672.3K
$4.0M
Q1 24
$-37.2K
$27.0M
Free Cash Flow
BGLC
BGLC
NTRA
NTRA
Q4 25
$960.1K
$37.8M
Q3 25
$-1.2M
$37.0M
Q2 25
$-759.4K
$11.7M
Q1 25
$-833.1K
$22.6M
Q4 24
$215.2K
$34.8M
Q3 24
$-1.8M
$35.5M
Q2 24
$-674.1K
$-7.7M
Q1 24
$-59.1K
$6.7M
FCF Margin
BGLC
BGLC
NTRA
NTRA
Q4 25
198.5%
5.7%
Q3 25
-48.9%
6.2%
Q2 25
-33.6%
2.1%
Q1 25
-39.0%
4.5%
Q4 24
8.5%
7.3%
Q3 24
-68.5%
8.1%
Q2 24
-34.1%
-1.9%
Q1 24
-2.5%
1.8%
Capex Intensity
BGLC
BGLC
NTRA
NTRA
Q4 25
0.2%
5.4%
Q3 25
0.2%
3.8%
Q2 25
0.9%
4.7%
Q1 25
0.4%
4.3%
Q4 24
0.2%
3.8%
Q3 24
7.6%
3.7%
Q2 24
0.1%
2.8%
Q1 24
0.9%
5.5%
Cash Conversion
BGLC
BGLC
NTRA
NTRA
Q4 25
1.56×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-3.38×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons